TAR-200 for Treatment of BCG-Unresponsive, High-Risk NMIBC

An expert discusses how the SunRISe-1 phase 2b trial, presented at the European Society for Medical Oncology 2024 Congress (ESMO 2024), evaluated TAR-200 alone and with cetrelimab in BCG-unresponsive, high-risk non–muscle invasive bladder cancer (NMIBC). TAR-200 monotherapy achieved an 84% complete response rate, with most adverse events being mild to moderate. The combination therapy showed higher rates of severe adverse events. TAR-200 is particularly promising for patient’s ineligible for or refusing radical cystectomy.

EP: 1.Drug Delivery Systems in NMIBC

Now Viewing

EP: 2.TAR-200 for Treatment of BCG-Unresponsive, High-Risk NMIBC

EP: 3.Adoption of Emerging Delivery Systems and Future Outlook for NMIBC

Video content above is prompted by the following:

• The results of the SunRISe-1 phase 2b clinical trial, which investigated the use of the TAR-200 delivery system alone vs with cetrelimab, were recently presented at ESMO 2024.
• What are your impressions of the safety and efficacy data?
• Which patients might be the best candidates for the TAR-200 delivery system based on this data?

Related Videos